東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Gene Patents and Access to Genetic D...

Khanijoun, Harleen.

Linked to FindBook

Google Book

Amazon

博客來

Gene Patents and Access to Genetic Diagnostic Tests.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Gene Patents and Access to Genetic Diagnostic Tests./
Author:	Khanijoun, Harleen.
Description:	68 p.
Notes:	Source: Masters Abstracts International, Volume: 51-05.
Contained By:	Masters Abstracts International51-05(E).
Subject:	Patent Law. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=MR85237
ISBN:	9780494852378

Gene Patents and Access to Genetic Diagnostic Tests.
Khanijoun, Harleen.

Gene Patents and Access to Genetic Diagnostic Tests. - 68 p.

Source: Masters Abstracts International, Volume: 51-05.

Thesis (LL.M.)--University of Toronto (Canada), 2012.

The utilitarian theory contemplates rewarding the risks of inventors by providing them with a defined period of exclusivity to recoup their investment. For inventions requiring further investment, patents enable the creation of financial relationships between inventors and investors by providing patent exclusivity during the commercialization process. Innovation, contrasted from invention and conceptualized as commercialization, however, does not necessarily form the best means for delivering to the public inventions intended to improve health. Although patent policy conflates the economic growth and health improvement objectives of innovation, these goals do not always align. While the exercise of BRCA patents instantiates exclusive practicing of patents that failed to adequately deliver health technology, the patent system does not need significant change. Rather, to maintain the expectations of patent holders while balancing the needs of the public, current practices should continue with the encouragement of the creation of voluntary patent pools.

ISBN: 9780494852378Subjects--Topical Terms:

1679968
Patent Law.

Gene Patents and Access to Genetic Diagnostic Tests.
LDR:01911nam a2200289 4500 001 1958679
005 20140426115101.5
008 150210s2012 ||||||||||||||||| ||eng d
020 $a 9780494852378
035 $a (MiAaPQ)AAIMR85237
035 $a AAIMR85237
040 $a MiAaPQ $c MiAaPQ
100 1 $a Khanijoun, Harleen. $3 2093830
245 1 0 $a Gene Patents and Access to Genetic Diagnostic Tests.
300 $a 68 p.
500 $a Source: Masters Abstracts International, Volume: 51-05.
500 $a Adviser: Ariel Katz.
502 $a Thesis (LL.M.)--University of Toronto (Canada), 2012.
520 $a The utilitarian theory contemplates rewarding the risks of inventors by providing them with a defined period of exclusivity to recoup their investment. For inventions requiring further investment, patents enable the creation of financial relationships between inventors and investors by providing patent exclusivity during the commercialization process. Innovation, contrasted from invention and conceptualized as commercialization, however, does not necessarily form the best means for delivering to the public inventions intended to improve health. Although patent policy conflates the economic growth and health improvement objectives of innovation, these goals do not always align. While the exercise of BRCA patents instantiates exclusive practicing of patents that failed to adequately deliver health technology, the patent system does not need significant change. Rather, to maintain the expectations of patent holders while balancing the needs of the public, current practices should continue with the encouragement of the creation of voluntary patent pools.
590 $a School code: 0779.
650 4 $a Patent Law. $3 1679968
650 4 $a Law. $3 600858
650 4 $a Health Sciences, Medical Ethics. $3 1669715
690 $a 0562
690 $a 0398
690 $a 0497
710 2 $a University of Toronto (Canada). $b Law. $3 2093829
773 0 $t Masters Abstracts International $g 51-05(E).
790 $a 0779
791 $a LL.M.
792 $a 2012
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=MR85237